Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis : 48-week results from the EMBARK study [PDF]
, 2015 Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).
Bonin, Randi +15 more
core +1 more source
The role of positive information provision in open‐label placebo effects
Applied Psychology: Health and Well-Being, 2023 Abstract Open label placebos (OLPs) appear generally efficacious among clinical samples, but the empirical evidence regarding their use in non‐clinical and sub‐clinical samples, as well as when administered independent of a convincing rationale, is mixed. Healthy participants ( N
Kirsten Barnes +4 more
openaire +2 more sources
Are old-old patients with major depression more likely to relapse than young-oldpatients during continuation treatment with escitalopram? [PDF]
, 2011 International audienceBACKGROUND: Escitalopram has shown efficacy and tolerability in the prevention of relapse in elderly patients with major depressive disorder (MDD).
Constantine G Lyketsos +3 more
core +3 more sources
Effects of Open- and Closed-Label Nocebo and Placebo Suggestions on Itch and Itch Expectations
Frontiers in Psychiatry, 2019 Placebo and nocebo effects have been shown to influence subjective symptoms such as itch. These effects can be induced by influencing outcome expectations through, for example, combining the application of an inert substance (e.g., a cream) with verbal ...
Stefanie H. Meeuwis +12 more
doaj +1 more source
Effects of Open-Label Placebos on State Anxiety and Glucocorticoid Stress Responses [PDF]
Brain Sciences, 2021 Stress belongs to the most frequent negative feelings people are confronted with in daily life. Strategies against acute stress include, e.g., relaxation techniques or medications, but it is also known that placebos can successfully reduce negative emotional stress.
Schaefer, Michael +2 more
openaire +3 more sources
Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: a systematic review and meta-analysis [PDF]
, 2017 Introduction: Neurotrophic factors (NTFs) have been evaluated for neuroprotective effects in Parkinson's disease (PD). However, clinical trials examining the efficacy of intracerebral administration of NTFs on motor symptoms in PD have produced mixed ...
Hegarty, Shane V. +3 more
core +1 more source
Placebo effects in health and disease : how expectations shape treatment outcomes [PDF]
, 2016 The context in which a medical treatment is administrated influences treatment outcomes. As of today, the health care system has little knowledge about the non-specific components that contribute to the positive effect of a given therapy, often referred ...
Rosén, Annelie
core +1 more source
Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits?
BMJ, 2018 Results from small clinical trials suggesting that placebos can be ethically and effectively used in clinical practice warrant further study, argue Ted Kaptchuk and Franklin ...
Ted J, Kaptchuk, Franklin G, Miller
openaire +3 more sources
The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]
, 2014 INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core +2 more sources
Medicines, 2020 Background: Placebo has been studied for many years and is ever-present in healthcare. In clinical practice, its use is limited by ethical issues raised by the deception entailed by its administration.
Leo Druart +6 more
doaj +1 more source